EGFR and non-small cell lung carcinoma: In a study of the clinical activity of osimertinib in 45 EGFR-mutant NSCLC patients previously treated with rociletinib, subsequent treatment with osimertinib still achieved a brain disease control rate (response + SD) of 88% (71).